www.fdanews.com/articles/196730-novartis-to-launch-phase-3-hydroxychloroquine-trial-for-covid-19
Novartis to Launch Phase 3 Hydroxychloroquine Trial for COVID-19
April 21, 2020
Novartis said it will begin enrollment in the next few weeks for a phase 3 clinical trial to evaluate hydroxychloroquine for treatment of hospitalized COVID-19 patients. The trial will include more than 440 participants at more than a dozen U.S. sites.
If the product is approved for COVID-19, Novartis will release its intellectual property relating to hydroxychloroquine for use by other drugmakers.
The company also committed to donating 130 million hydroxychloroquine tablets for global clinical research efforts.